GSK plc or Takeda Pharmaceutical Company Limited: Who Manages SG&A Costs Better?

GSK vs. Takeda: SG&A Cost Management Showdown

__timestampGSK plcTakeda Pharmaceutical Company Limited
Wednesday, January 1, 20148246000000612613000000
Thursday, January 1, 20159232000000650773000000
Friday, January 1, 20169366000000619061000000
Sunday, January 1, 20179672000000628106000000
Monday, January 1, 20189915000000717599000000
Tuesday, January 1, 201911402000000964737000000
Wednesday, January 1, 202011456000000875663000000
Friday, January 1, 202110975000000886361000000
Saturday, January 1, 20228372000000997309000000
Sunday, January 1, 202393850000001053819000000
Monday, January 1, 20241053819000000
Loading chart...

In pursuit of knowledge

GSK vs. Takeda: A Decade of SG&A Management

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Takeda Pharmaceutical Company Limited have shown contrasting approaches. From 2014 to 2023, GSK's SG&A expenses fluctuated modestly, peaking in 2020 at approximately $11.5 billion before dropping to around $9.4 billion in 2023. In contrast, Takeda's expenses soared, starting at $612 billion in 2014 and reaching over $1 trillion by 2023, marking a staggering 72% increase.

This divergence highlights different strategic priorities. GSK's relatively stable expenses suggest a focus on cost control, while Takeda's rising costs may reflect aggressive expansion or investment in innovation. Notably, data for GSK in 2024 is missing, leaving room for speculation on future trends. As these giants navigate the evolving pharmaceutical landscape, their SG&A strategies will be pivotal in shaping their competitive edge.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025